Do analysts rate CANF or IMAC?

Can-Fite BioPharma currently has a consensus price target of $44.00, indicating a potential upside of 1,201.78%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Can-Fite BioPharma is more favorable than IMAC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor CANF or IMAC?

In the previous week, IMAC had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for IMAC and 1 mentions for Can-Fite BioPharma. IMAC's average media sentiment score of 0.16 beat Can-Fite BioPharma's score of 0.00 indicating that IMAC is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IMAC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer IMAC or PTHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, IMAC or PTHL?

Pheton has lower revenue, but higher earnings than IMAC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IMAC $15.22M 0.03 -$10.54M -$0.27 N/A Pheton $305.22K 6.04 -$660K N/A N/A

Is IMAC or PTHL more profitable?

Pheton has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Pheton's return on equity of 0.00% beat IMAC's return on equity. Company Net Margins Return on Equity Return on Assets IMAC -75.40% -52.17% -34.51% Pheton N/A N/A N/A

Does the media refer more to IMAC or PTHL?

In the previous week, IMAC had 1 more articles in the media than Pheton. MarketBeat recorded 2 mentions for IMAC and 1 mentions for Pheton. IMAC's average media sentiment score of 0.16 beat Pheton's score of 0.00 indicating that IMAC is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IMAC 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pheton 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IVF or IMAC?

INVO Fertility presently has a consensus target price of $20.00, suggesting a potential upside of 1,823.08%. Given INVO Fertility's stronger consensus rating and higher probable upside, equities analysts plainly believe INVO Fertility is more favorable than IMAC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, IVF or IMAC?

IMAC has higher revenue and earnings than INVO Fertility. IMAC is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INVO Fertility $6.84M 0.27 -$25.13M -$352.18 N/A IMAC $15.22M 0.03 -$10.54M -$0.27 N/A

Is IVF or IMAC more profitable?

IMAC has a net margin of -75.40% compared to INVO Fertility's net margin of -183.75%. IMAC's return on equity of -52.17% beat INVO Fertility's return on equity. Company Net Margins Return on Equity Return on Assets INVO Fertility -183.75% -420.62% -45.21% IMAC -75.40% -52.17% -34.51%

Do analysts prefer FLGC or IMAC?

Flora Growth presently has a consensus price target of $30.00, suggesting a potential upside of 1,718.18%. Given Flora Growth's stronger consensus rating and higher possible upside, research analysts clearly believe Flora Growth is more favorable than IMAC. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, FLGC or IMAC?

IMAC has lower revenue, but higher earnings than Flora Growth. IMAC is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Flora Growth $57.61M 0.03 -$15.91M -$32.49 N/A IMAC $15.22M 0.03 -$10.54M -$0.27 N/A

Is FLGC or IMAC more profitable?

Flora Growth has a net margin of -32.03% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Flora Growth's return on equity. Company Net Margins Return on Equity Return on Assets Flora Growth -32.03% -64.02% -34.46% IMAC -75.40% -52.17% -34.51%

Which has higher earnings and valuation, IMAC or BPTH?

IMAC has higher revenue and earnings than Bio-Path. IMAC is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IMAC $15.22M 0.03 -$10.54M -$0.27 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is IMAC or BPTH more profitable?

Bio-Path has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets IMAC -75.40% -52.17% -34.51% Bio-Path N/A -2,842.40% -337.48%

IMAC (IMAC) Competitors

$0.02 0.00 (-13.51%)

As of 07/20/2026

Compare

IMAC vs. CANF, PTHL, IVF, FLGC, and BPTH

Should you buy IMAC stock or one of its competitors? MarketBeat compares IMAC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IMAC include Can-Fite BioPharma (CANF), Pheton (PTHL), INVO Fertility (IVF), Flora Growth (FLGC), and Bio-Path (BPTH). These companies are all part of the "medical" sector.

How does IMAC compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Can-Fite BioPharma has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Can-Fite BioPharma's return on equity of 0.00% beat IMAC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
IMAC	-75.40%	-52.17%	-34.51%

Can-Fite BioPharma has higher earnings, but lower revenue than IMAC. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.47	-$7.63M	-$22.80	N/A
IMAC	$15.22M	0.03	-$10.54M	-$0.27	N/A

In the previous week, IMAC had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for IMAC and 1 mentions for Can-Fite BioPharma. IMAC's average media sentiment score of 0.16 beat Can-Fite BioPharma's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IMAC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Can-Fite BioPharma has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market.

Can-Fite BioPharma currently has a consensus price target of $44.00, indicating a potential upside of 1,201.78%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Can-Fite BioPharma is more favorable than IMAC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Can-Fite BioPharma beats IMAC on 9 of the 16 factors compared between the two stocks.

How does IMAC compare to Pheton?

IMAC (NASDAQ:IMAC) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, IMAC had 1 more articles in the media than Pheton. MarketBeat recorded 2 mentions for IMAC and 1 mentions for Pheton. IMAC's average media sentiment score of 0.16 beat Pheton's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IMAC	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pheton	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

24.3% of IMAC shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Pheton's return on equity of 0.00% beat IMAC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
Pheton	N/A	N/A	N/A

Pheton has lower revenue, but higher earnings than IMAC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.03	-$10.54M	-$0.27	N/A
Pheton	$305.22K	6.04	-$660K	N/A	N/A

Summary

Pheton beats IMAC on 7 of the 12 factors compared between the two stocks.

How does IMAC compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

INVO Fertility presently has a consensus target price of $20.00, suggesting a potential upside of 1,823.08%. Given INVO Fertility's stronger consensus rating and higher probable upside, equities analysts plainly believe INVO Fertility is more favorable than IMAC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

INVO Fertility has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market. Comparatively, IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

IMAC has a net margin of -75.40% compared to INVO Fertility's net margin of -183.75%. IMAC's return on equity of -52.17% beat INVO Fertility's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-183.75%	-420.62%	-45.21%
IMAC	-75.40%	-52.17%	-34.51%

12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 0.4% of INVO Fertility shares are held by company insiders. Comparatively, 10.0% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, IMAC had 2 more articles in the media than INVO Fertility. MarketBeat recorded 2 mentions for IMAC and 0 mentions for INVO Fertility. IMAC's average media sentiment score of 0.16 beat INVO Fertility's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company	Overall Sentiment
INVO Fertility	Neutral
IMAC	Neutral

IMAC has higher revenue and earnings than INVO Fertility. IMAC is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.84M	0.27	-$25.13M	-$352.18	N/A
IMAC	$15.22M	0.03	-$10.54M	-$0.27	N/A

Summary

IMAC beats INVO Fertility on 10 of the 16 factors compared between the two stocks.

How does IMAC compare to Flora Growth?

Flora Growth (NASDAQ:FLGC) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Flora Growth has a net margin of -32.03% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
IMAC	-75.40%	-52.17%	-34.51%

36.0% of Flora Growth shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 2.3% of Flora Growth shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Flora Growth presently has a consensus price target of $30.00, suggesting a potential upside of 1,718.18%. Given Flora Growth's stronger consensus rating and higher possible upside, research analysts clearly believe Flora Growth is more favorable than IMAC.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, IMAC had 2 more articles in the media than Flora Growth. MarketBeat recorded 2 mentions for IMAC and 0 mentions for Flora Growth. Flora Growth's average media sentiment score of 1.26 beat IMAC's score of 0.16 indicating that Flora Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Flora Growth	Positive
IMAC	Neutral

Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

IMAC has lower revenue, but higher earnings than Flora Growth. IMAC is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.03	-$15.91M	-$32.49	N/A
IMAC	$15.22M	0.03	-$10.54M	-$0.27	N/A

Summary

Flora Growth beats IMAC on 11 of the 16 factors compared between the two stocks.

How does IMAC compare to Bio-Path?

IMAC (NASDAQ:IMAC) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

IMAC has higher revenue and earnings than Bio-Path. IMAC is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.03	-$10.54M	-$0.27	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, indicating that its share price is 151% less volatile than the broader market.

Bio-Path has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
Bio-Path	N/A	-2,842.40%	-337.48%

In the previous week, IMAC had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for IMAC and 0 mentions for Bio-Path. IMAC's average media sentiment score of 0.16 beat Bio-Path's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company	Overall Sentiment
IMAC	Neutral
Bio-Path	Neutral

24.3% of IMAC shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

IMAC beats Bio-Path on 9 of the 12 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMAC vs. The Competition

Export

Metric	IMAC	Specialty Outpatient Clinics Industry	Medical Sector	NASDAQ Exchange
Market Cap	$424K	$614.50K	$6.80B	$12.32B
Dividend Yield	N/A	N/A	2.67%	9.67%
P/E Ratio	-0.06	N/A	26.92	24.18
Price / Sales	0.03	0.03	483.73	80.05
Price / Cash	N/A	N/A	49.71	59.37
Price / Book	0.02	0.02	10.67	6.25
Net Income	-$10.54M	-$10.54M	$3.60B	$331.66M
7 Day Performance	N/A	N/A	-1.00%	-1.32%
1 Month Performance	N/A	N/A	1.58%	-1.74%
1 Year Performance	N/A	N/A	24.12%	18.04%

IMAC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMAC IMAC	N/A	$0.02 -13.5%	N/A	-82.7%	$424K	$15.22M	N/A	106	Gap Down
CANF Can-Fite BioPharma	1.6751 of 5 stars	$3.32 +1.2%	$44.00 +1,225.3%	-83.7%	$2.18M	$405K	N/A	8	Gap Down
PTHL Pheton	N/A	$0.32 -2.3%	N/A	-98.8%	$2.10M	$305.22K	N/A	11	Gap Down
IVF INVO Fertility	1.7257 of 5 stars	$1.13 flat	$20.00 +1,669.9%	-99.0%	$2.02M	$6.84M	N/A	10
FLGC Flora Growth	2.0644 of 5 stars	$1.92 +5.5%	$30.00 +1,462.5%	-93.5%	$2.01M	$57.61M	N/A	280	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMAC) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IMAC (IMAC) Competitors

IMAC vs. CANF, PTHL, IVF, FLGC, and BPTH

How does IMAC compare to Can-Fite BioPharma?

Summary

How does IMAC compare to Pheton?

Summary

How does IMAC compare to INVO Fertility?

Summary

How does IMAC compare to Flora Growth?

Summary

How does IMAC compare to Bio-Path?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IMAC (IMAC) Competitors

IMAC vs. CANF, PTHL, IVF, FLGC, and BPTH

How does IMAC compare to Can-Fite BioPharma?

Is CANF or IMAC more profitable?

Which has higher earnings and valuation, CANF or IMAC?

Does the media favor CANF or IMAC?

Do insiders & institutionals believe in CANF or IMAC?

Which has more volatility & risk, CANF or IMAC?

Do analysts rate CANF or IMAC?

Summary

How does IMAC compare to Pheton?

Does the media refer more to IMAC or PTHL?

Do insiders and institutionals hold more shares of IMAC or PTHL?

Which has more volatility & risk, IMAC or PTHL?

Do analysts prefer IMAC or PTHL?

Is IMAC or PTHL more profitable?

Which has better earnings & valuation, IMAC or PTHL?

Summary

How does IMAC compare to INVO Fertility?

Do analysts recommend IVF or IMAC?

Which has more volatility & risk, IVF or IMAC?

Is IVF or IMAC more profitable?

Do institutionals and insiders have more ownership in IVF or IMAC?

Does the media prefer IVF or IMAC?

Which has preferable earnings and valuation, IVF or IMAC?

Summary

How does IMAC compare to Flora Growth?

Is FLGC or IMAC more profitable?

Do insiders and institutionals have more ownership in FLGC or IMAC?

Do analysts prefer FLGC or IMAC?

Does the media favor FLGC or IMAC?

Which has more risk & volatility, FLGC or IMAC?

Which has better earnings and valuation, FLGC or IMAC?

Summary

How does IMAC compare to Bio-Path?

Which has higher earnings and valuation, IMAC or BPTH?

Which has more volatility & risk, IMAC or BPTH?

Is IMAC or BPTH more profitable?

Does the media refer more to IMAC or BPTH?

Do insiders & institutionals have more ownership in IMAC or BPTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools